ALL Clinical Trial
Official title:
The Copper Metabolism MURR1 Domain 7 (COMMD7) Gene Expression in Acute Lymphoblastic Leukemia
- study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia. - investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .
Acute lymphoblastic leukemia (ALL) is a neoplastic disorder of lymphoid progenitor cells characterized by diverse cytogenetic and molecular abnormalities with peaks of prevalence for 2-5-year-old patients and those older than 50. Treatment strategies using risk-adapted chemotherapy cure more than 80% of childhood cases, but around 20 to 30% relapse developing serious complications including death.( 1) In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes.(2) The copper metabolism MURR1 domain (COMMD) protein family involved in tumor development and progression in several types of human cancer, but little is known about the function of COMMD proteins in hematological malignancy. (3) COMMD7, a member of the COMMD, which is located on chromosome 20q11.21, has been reported associated with tumor progression in human solid cancers [4]. COMMD7 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) cells, associated with poor prognosis. [5]. Another study revealed that COMMD7-overexpressed hepatocellular carcinoma (HCC) cells promoted the proliferation of naïve HCC cells (6) A recent study was found that high expression of COMMD7 is a potential biomarker for adverse outcomes and poor prognosis in AML. (7) . However, to date, the expression of COMMD7 in acute lymphoblastic leukemia and its prognostic value remain unclear. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
| Recruiting |
NCT05009537 -
Optical Genome Mapping in Hematological Malignancies
|
||
| Terminated |
NCT01230788 -
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
|
N/A | |
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05461625 -
ACL Reconstruction With/Without ALL Reconstruction
|
N/A | |
| Recruiting |
NCT02990572 -
Amish/Mennonite Research Contact Registry
|
||
| Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
| Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Recruiting |
NCT04601584 -
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02861209 -
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
|
N/A | |
| Completed |
NCT01012492 -
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
|
Phase 2 | |
| Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03571321 -
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
| Active, not recruiting |
NCT03154346 -
Project Baseline Health Study
|
||
| Terminated |
NCT01532635 -
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
|
Phase 2 | |
| Completed |
NCT01319864 -
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
|
Phase 1 | |
| Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 |